Erratum: The essential role of TNIK gene amplification in gastric cancer growth (Oncogenesis (2014) 3 (e89) DOI:10.1038/oncsis.2014.2);The essential role of TNIK gene amplification in gastric cancer growth

Oncogenesis

Volumn 3, Issue 2, 2014, Pages

  Yu, D H ^a   Zhang, X ^a   Wang, H ^a,b   Zhang, L ^c   Chen, H ^d   Hu, M ^a   Dong, Z ^a   Zhu, G ^a   Qian, Z ^a   Fan, J ^a   Su, X ^a   Xu, Y ^a   Zheng, L ^a   Dong, H ^a   Yin, X ^a   Ji, Q ^a   Ji, J ^c  

^a ASTRAZENECA   (United Kingdom)

^b FUDAN UNIVERSITY   (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

gastric cancer; TNIK; Wnt

Indexed keywords

SMALL INTERFERING RNA;

ARTICLE; BREAST CANCER CELL LINE; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DOSAGE; GENE SILENCING; HUMAN; HUMAN CELL; HYBRIDIZATION; PATIENT SELECTION; PRIORITY JOURNAL; RNA INTERFERENCE; STOMACH CANCER; STOMACH CARCINOGENESIS; TNIK GENE; TUMOR GENE; UPREGULATION; WNT SIGNALING PATHWAY;

EID: 84923355230     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.9     Document Type: Erratum

References (17)

1. Fu CA, Shen M, Huang BC, Lasaga J, Payan DG, Luo Y. TNIK, a novel member of the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and regulates the cytoskeleton. J Biol Chem 1999; 274: 30729-30737.
2. Taira K, Umikawa M, Takei K, Myagmar BE, Shinzato M, Machida N et al. The Traf2-and Nck-interacting kinase as a putative effector of Rap2 to regulate actin cytoskeleton. J Biol Chem 2004; 279: 49488-49496.
3. Mahmoudi T, Li VS, Ng SS, Taouatas N, Vries RG, Mohammed S et al. The kinase TNIK is an essential activator of Wnt target genes. EMBO J 2009; 28: 3329-3340.
4. Shitashige M, Satow R, Jigami T, Aoki K, Honda K, Shibata T et al. Traf2-and Nckinteracting kinase is essential for Wnt signaling and colorectal cancer growth. Cancer Res 2010; 70: 5024-5033.
5. Yamada T, Shitashige M, Yokota K, Sawa M, Mariyama H. TNIK inhibitor and the use. W0 2010/064111 A1.
6. Nusse R, Varmus H. Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J 2012; 31: 2670-2684.
7. Pecina-Slaus N. Wnt signal transduction pathway and apoptosis: a review. Cancer Cell Int 2010; 10: 22.
8. Saito-Diaz K, Chen TW, Wang X, Thorne CA, Wallace HA, Page-McCaw A et al. The way Wnt works: components and mechanism. Growth Factors 2013; 31: 1-31.
9. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11-26.
10. Hussain NK, Hsin H, Huganir RL, Sheng M. MINK and TNIK differentially act on Rap2-mediated signal transduction to regulate neuronal structure and AMPA receptor function. J Neurosci 2010; 30: 14786-14794.
11. Kawabe H, Neeb A, Dimova K, Young Jr SM, Takeda M, Katsurabayashi S et al. Regulation of Rap2A by the ubiquitin ligase Nedd4-1 controls neurite development. Neuron 2010; 65: 358-372.
12. Shkoda A, Town JA, Griese J, Romio M, Sarioglu H, Knofel T et al. The germinal center kinase TNIK is required for canonical NF-kappaB and JNK signaling in B-cells by the EBV oncoprotein LMP1 and the CD40 receptor. PLoS Biol 2012; 10: e1001376.
13. Maiese K, Chong ZZ, Shang YC, Wang S. Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin Ther Targets 2012; 16: 1203-1214.
14. Parkhitko AA, Favorova OO, Henske EP. Autophagy: mechanisms, regulation, and its role in tumorigenesis. Biochemistry (Mosc) 2013; 78: 355-367.
15. Li J, Davies BR, Han S, Zhou M, Bai Y, Zhang J et al. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patientderived gastric cancer xenograft model with PTEN loss to Taxotere. J Transl Med 2013; 11: 241.
16. Ho KK, Parnell KM, Yuan Y, Xu Y, Kultgen SG, Hamblin S et al. Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors. Bioorg Med Chem Lett 2013; 23: 569-573.
17. Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 2013; 19: 2572-2583.